Greenwich LifeSciences (NASDAQ:GLSI) Trading Up 2.4% – Should You Buy?

Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) traded up 2.4% during trading on Tuesday . The stock traded as high as $19.35 and last traded at $19.01. 93,500 shares were traded during mid-day trading, a decline of 33% from the average session volume of 139,999 shares. The stock had previously closed at $18.57.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GLSI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Wall Street Zen downgraded shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Greenwich LifeSciences has a consensus rating of “Hold” and an average target price of $47.50.

Greenwich LifeSciences Price Performance

The stock has a market capitalization of $279.07 million, a price-to-earnings ratio of -12.11 and a beta of 1.40. The firm has a fifty day moving average of $23.63 and a 200 day moving average of $24.71.

Institutional Investors Weigh In On Greenwich LifeSciences

Several hedge funds have recently bought and sold shares of GLSI. Marshall Wace LLP purchased a new position in shares of Greenwich LifeSciences during the 2nd quarter valued at approximately $509,000. Bank of New York Mellon Corp boosted its holdings in Greenwich LifeSciences by 235.5% during the first quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after buying an additional 32,657 shares in the last quarter. Virtu Financial LLC purchased a new stake in Greenwich LifeSciences during the fourth quarter worth $605,000. Man Group plc purchased a new stake in Greenwich LifeSciences during the fourth quarter worth $590,000. Finally, Sei Investments Co. acquired a new stake in Greenwich LifeSciences during the first quarter valued at $627,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.